Yu Kagami, the co-founder of our company in April 2022, has served as CEO since incorporation. Prior to co-founding our company, Yu was engaged in drug review work at the Pharmaceuticals and Medical Devices Agency (PMDA) and in regulatory affairs, clinical development at Janssen Pharmaceuticals. Yu received a Ph.D. in 2016 at the Graduate School of Pharmaceutical Sciences of the University of Tokyo in research on the development of fluorescent dyes.

Shingo Sakamoto, Ph.D., the co-founder of our company in April 2022, has served as CTO since incorporation. Shingo has been developing the single-molecule enzyme activity-based protein profiling (SEAP) technology since he began his research at the Faculty of Pharmaceutical Sciences of the University of Tokyo. Shingo received the Grand Prize, HAX Tokyo Award, and Mentor Award in the "Entrepreneurship Development" section of EDGE-NEXT Development of MEXT in 2020.

Toshihiro Uno has served as Chief Business Officer since October 2023. Prior to joining Cosomil, he had multiple experiences such as Marketing Director at Janssen Pharmaceuticals, responsible for Strategic Marketing of New Products for Oncology across Asia Pacific Region as well as in Japan, followed by Commercial Operations Director at Abbott, responsible for driving competitiveness of sales organization. He started his career as Sales Rep followed by Marketing Brand Leader at pharmaceutical companies after graduating from University of Houston. He aspires to contribute to conquering cancer while spending most of his career in Oncology.

Toru Komatsu, Ph.D., the co-founder of our company in April 2022, has served as Scientific Advisor since incorporation. Currently, Toru is an associate professor at the Graduate School of Pharmaceutical Sciences of the University of Tokyo after working as a postdoctoral fellow at Johns Hopkins University and Scripps Research Institute in the U.S. He also served as a JST-PRESTO researcher (concurrent position) from 2013 to 2017. Toru specializes in chemical biology and drug discovery chemistry.

Rikiya Watanabe, Ph.D., the co-founder of our company in April 2022, has served as Scientific Advisor since incorporation. After working as an assistant professor and lecturer at the Graduate School of Engineering of the University of Tokyo, and as a JST PRESTO researcher (concurrent position), Rikiya is currently a chief scientist at RIKEN, and an adjunct professor at the Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University. Rikiya specializes in single molecule biophysics and bioMEMS.

Tadahaya Mizuno, Ph.D. is an Assistant Professor in the Department of Molecular Pharmacokinetics at the Graduate School of Pharmaceutical Sciences of the University of Tokyo. He specializes in bioinformatics and chemoinformatics.

After serving as Assistant Professor of Oral Surgery at Tokyo Medical University, Postdoctoral Fellow at PMDA, Laboratory Head and Unit Director at the National Cancer Center Research Institute, and Director of the Division of Early Diagnostic Biomarker Development at the same institute, Kazufumi is currently a Graduate Professor at the Department of Bioregulation, Graduate School of Medicine, Nippon Medical School. He specializes in tumor biology and biomarker discovery.